

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A transdermal therapeutic system for continuous administration of pramipexol comprising a backing layer and ~~at least one~~ a first active ingredient-containing polymer layer which comprises the active ingredient pramipexol, wherein the first active ingredient-containing polymer layer comprises at least one pressure-sensitive adhesive polymer selected from ~~the group of silicones, polyisobutylenes, polybutenes, styrene-isoprene-styrene block copolymers in combination with resins, and of~~ carboxyl group-free polyacrylates, where the active ingredient pramipexol is present ~~therein~~ in said first active ingredient-containing polymer layer in a proportion of between 10 and 40 % by weight and said transdermal therapeutic system includes an additional active ingredient-containing layer, whereby the transdermal therapeutic system releases the active ingredient pramipexol with a flux rate greater than 5 $\mu\text{g}/\text{cm}^2$ hr over the period between 24 hours after administration to 72 hours after administration .

2. (Currently Amended) The transdermal therapeutic system as claimed in claim 1, which further comprises ~~a further~~ at least one element selected from the group consisting of a pressure-sensitive adhesive layer, an additional a membrane which controls the rate of release of pramipexol, an additional active ingredient-containing layer or an additional a supporting layer.

3. (Currently Amended) The transdermal therapeutic system as claimed in claim 1, wherein the pressure-sensitive adhesive polymer is a carboxyl group-free polyacrylate which can be prepared by polymerization of a monomer mixture of at least one acrylic ester or methacrylic ester with linear, branched or cyclic aliphatic C₁-C₁₂ substituents without other functional

groups, and at least one hydroxyl group-containing acrylic ester or one hydroxyl group-containing methacrylic ester in a proportion by weight of less than 10%.

4. (Canceled) Please cancel Claim 4.

5. (Canceled) Please cancel Claim 5.

6. (Previously Presented) The transdermal therapeutic system as claimed in claim 3, wherein the monomer mixture additionally comprises vinyl acetate in a proportion by weight of less than 50 %.

7. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present in the active ingredient-containing polymer layer in dissolved, emulsified and/or dispersed form.

8. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer, *R*-(+) enantiomer or racemic mixture of these two enantiomers in the active ingredient-containing polymer layer.

9. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present as a free base, hydrate, solvate and/or pharmaceutically acceptable salt in the active ingredient-containing polymer layer.

10. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present as *S*-(-) enantiomer in the form of a free base in the active ingredient-containing polymer layer.

11. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein said transdermal therapeutic system delivers the active ingredient pramipexol continuously to a patient's skin over a period of from 4 to 7 days.

12. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, which is able to release the active ingredient pramipexol with a flux rate greater than $5 \mu\text{g}/\text{cm}^2 \text{ h}$ over the period between 24 hours after administration to 168 h after administration.

13. (Canceled) Please cancel Claim 13.

14. (Currently Amended) The transdermal therapeutic system as claimed in claim 1, wherein the active ingredient pramipexol is present ~~therein~~ in said first active ingredient-containing polymer layer in a proportion of between 10 and 25 % by weight.

15. (Previously Presented) The transdermal therapeutic system as claimed in claim 1, wherein the daily delivery rate of pramipexol is between 0.1-10 mg.

16. (Currently Amended) The transdermal therapeutic system as claimed in claim 3 [[6]], wherein the pressure-sensitive adhesive monomer mixture additionally comprises said vinyl acetate ~~is present~~ in a proportion of less than 25% by weight.

17. (Currently Amended) The transdermal therapeutic system as claimed in claim 1 [[15]], wherein the daily delivery rate of pramipexol is between 0.5 to 4.5 mg.

18. (New) A transdermal therapeutic system for continuous administration of pramipexol comprising (i) a backing layer, (ii) a first active ingredient-containing polymer layer comprising pramipexol in a proportion of between 10 and less than 75 % by weight and (iii) a second active ingredient-containing polymer layer comprising pramipexol in a proportion of between 2 and 10 % by weight,

wherein the first and second active ingredient-containing polymer layer comprise pressure-sensitive adhesive polymer consisting of carboxyl group-free polyacrylates,

and said transdermal therapeutic system releases the active ingredient pramipexol with a flux rate greater than $5 \mu\text{g}/\text{cm}^2 \text{ hr}$ over the period between 24 hours after administration to 72 hours after administration in the absence of an excipient or penetration-promoter.